Morgan Stanley Upgrades Allergen (AGN) to Overweight
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/12/2026
- Wall Street ends higher as investors turn to earnings season
- Oil prices settle lower on hopes for smoother shipping in Strait of Hormuz
- The real reason Meta shares are surging has nothing to do with its new AI model
- Stifel lifts Shopify to Buy, sees agentic commerce as next growth catalyst
- Delta Air Lines stock climbs on earnings beat and strong guidance
- Almonty Industries (ALM) PT Raised to $33 at DA Davidson
- Former emir of Qatar, Sheikh Hamad bin Khalifa Al Thani, dies at 74
- JPMorgan analysts name top short ideas for third quarter 2026
- The real reason Meta shares are surging has nothing to do with its new AI model
- Wall Street ends higher as investors turn to earnings season
Supreme Court divided over legality of patent reviews
November 27, 2017 11:34 AM ESTBy Andrew Chung
WASHINGTON (Reuters) - U.S. Supreme Court justices on Monday appeared divided over whether a federal agency's in-house process for challenging patents violates the constitutional rights of patent owners, leaving the fate of a system that has led to a high rate of patent cancellations uncertain.
In one of the most important Supreme Court patent cases in years, the nine justices heard an hour of arguments in a dispute over the U.S. Patent and Trademark Office's patent review proceeding, known as inter partes review (IPR). A decision to strike down the reviews could... More
Leerink Partners Resumes Allergen (AGN) at Outperform; Two Potential Blockbuster Absent from Valuation
November 27, 2017 6:29 AM EST(Updated - November 27, 2017 8:09 AM EST)
(updated to expand on analyst comments)
Leerink Partners resumes coverage on Allergen (NYSE: AGN) with a Outperform rating and a price target of $237.00.
Analyst Seamus Fernandez sees an emerging pipeline at a compelling... More
Barclays Starts Revance Therapeutic (RVNC) at Overweight
November 27, 2017 1:22 AM ESTBarclays initiates coverage on Revance Therapeutic (NASDAQ: RVNC) with a Overweight rating and a price target of $31.00.
Analyst Douglas Tsao comes out positive on the name citing a belief that the company's longer-acting toxin RT-002 will not displace Allergan's (NYSE:... More
